Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy

Molecular Therapy

Volumn 11, Issue 5, 2005, Pages 707-716

  Lee, Che Hsin ^a   Wu, Chao Liang ^a   Tai, Yun Sheng ^a   Shiau, Ai Li ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Cancer therapy; Cisplatin; Combination therapy; Hypoxia; Salmonella choleraesuis; Tumor targeted

Indexed keywords

CANCER ANTIBODY; CISPLATIN; DNA VACCINE; LIVE VACCINE; SALMONELLOSIS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL STRAIN; BACTERIOPHAGE; BACTERIUM DETECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MODEL; DNA VECTOR; IMMUNE RESPONSE; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG TUMOR; LYMPHOCYTIC INFILTRATION; MALE; METASTASIS INHIBITION; MONOTHERAPY; MOUSE; MOUSE STRAIN; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NONVIRAL GENE THERAPY; SALMONELLA CHOLERAESUIS; SUBCUTANEOUS TISSUE TUMOR; SURVIVAL TIME; SYSTEMIC THERAPY; T LYMPHOCYTE; TARGET CELL; TUMOR GROWTH;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CISPLATIN; LEUKOCYTE COUNT; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASMS; NEUTROPHILS; SALMONELLA; SURVIVAL RATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE; SALMONELLA CHOLERAESUIS;

EID: 17644426990     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.01.008     Document Type: Article

References (31)

1. J.M. Pawelek K.B. Low and D. Bermudes Tumor-targeted Salmonella as a novel anticancer vector Cancer Res. 57 1997 4537-4544
2. J.M. Pawelek K.B. Low and D. Bermudes Bacteria as tumour-targeting vectors Lancet Oncol. 4 2003 548-556
3. K.B. Low et al., Lipid A mutant Salmonella with suppressed virulence and TNF-α induction retain tumor-targeting in vivo Nat. Biotechnol. 17 1999 37-41
4. C.H. Lee C.L. Wu and A.L. Shiau Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models J. Gene Med. 6 2004 1382-1393
5. C.H. Lee C.L. Wu and A.L. Shiau Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model Cancer Gene Ther. 12 2005 175-184
6. X. Li et al., Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: Selective inhibitor of angiogenesis and hypoxic tumor growth Cancer Gene Ther. 10 2003 105-111
7. I. King et al., Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent Hum. Gene Ther. 13 2002 1225-1233
8. H. Yamada S. Matsumoto T. Matsumoto T. Yamada and U. Yamashita Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2 J. Urol. 164 2000 526-531
9. T.G. Graeber et al., Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours Nature 379 1996 88-91
10. J.M. Brown and A.J. Giaccia The unique physiology of solid tumors: opportunities (and problems) for cancer therapy Cancer Res. 58 1998 1408-1416
11. A.L. Shiau Y.L. Chen C.Y. Liao Y.S. Huang and C.L. Wu Prothymosin α enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuis Vaccine 19 2001 3947-3956
12. Y.A. Yu et al., Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins Nat. Biotechnol. 22 2004 313-320
13. H.W. Smith The immunization of mice, calves and pigs against Salmonella dublin and Salmonella cholera-esuis infections J. Hyg. (London) 63 1965 117-135
14. G.H. Tan et al., Combination of low-dose cisplatin and recombinant xenogeneic edoglin as a vaccine induces synergistic antitumor activities Int. J. Cancer 112 2004 701-706
15. K. Mishima et al., A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin Proc. Natl. Acad. Sci. USA 97 2000 8484-8489
16. J.H. Schiller and G. Bittner Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization Clin. Cancer Res. 5 1999 4287-4294
17. G. Bocci G. Francia S. Man J. Lawler and R.S. Kerbel Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy Proc. Natl. Acad. Sci. USA 100 2003 12917-12922
18. G. Klement et al., Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J. Clin. Invest. 105 2000 R15-R24
19. R.E. Merritt A. Mahtabifard R.E. Yamada R.G. Crystal and R.J. Korst Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer J. Thoracic Cardiovasc. Surg. 126 2003 1609-1617
20. S. Kasai S. Fujimoto K. Nitta H. Baba and T. Kunimoto Antitumor activity of polymorphonuclear leukocytes activated by a β-1,3-D-glucan J. Pharmacobiodyn. 14 1991 519-525
21. Y. Fujii S. Kimura S. Arai and F. Sendo In vivo antitumor effect of lymphokine-activated rodent polymorphonuclear leukocytes Cancer Res. 47 1987 6000-6005
22. K.D. Yang R.M. Stone C.S. Lee T.Y. Chao S.N. Cheng and M.F. Shaio Effect of picibanil (OK432) on neutrophil-mediated antitumor activity: implication of monocyte-derived neutrophil-activating factors Cancer Immunol. Immunother. 35 1992 277-282
23. D.D. Bannerman J.C. Tupper W.A. Ricketts C.F. Bennett R.K. Winn and J.M. Harlan A constitutive cytoprotective pathway protects endothelial cells from lipopolysaccharide-induced apoptosis J. Biol. Chem. 276 2001 14924-14932
24. C. Clairmont et al., Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium J. Infect. Dis. 181 2000 1996-2002
25. J.F. Toso et al., Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma J. Clin. Oncol. 20 2002 142-152
26. J. Nemunaitis et al., Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients Cancer Gene Ther. 10 2003 737-744
27. S.A. Soghomonyan et al., Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK Cancer Gene Ther. 12 2005 101-108
28. N.S. Forbes L.L. Munn D. Fukumura and R.K. Jain Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors Cancer Res. 63 2003 5188-5193
29. S.A. Rosenberg P.J. Spiess and D.E. Kleiner Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium J. Immunother. 25 2002 218-225
30. L.H. Dang C. Bettegowda D.L. Huso K.W. Kinzler and B. Vogelstein Combination bacteriolytic therapy for the treatment of experimental tumors Proc. Natl. Acad. Sci. USA 98 2001 15155-15160
31. J.L. Hsieh C.L. Wu C.H. Lee and A.L. Shiau Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1B-deleted adenovirus through the disruption of p53 function Clin. Cancer Res. 9 2003 338-345